JGC
URGN icon

J. Goldman & Co’s UroGen Pharma URGN Stock Holding History

J. Goldman & Co’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.83M Sell
212,775
-726,095
-77% -$19.7M 0.2% 135
2026
Q1 		$16.9M Buy
938,870
+425,567
+83% +$8.53M 0.49% 51
2025
Q4 		$12M Buy
+513,303
New +$11.1M 0.32% 90

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

J. Goldman & Co's URGN Position: Q2 2026 in Review

J. Goldman & Co reduced its UroGen Pharma (URGN) stake by 77% in Q2 2026, selling an estimated $19.7M and leaving 212,775 shares worth $7.83M. The position accounts for 0.2% of the portfolio, ranked #135.

J. Goldman & Co first reported a position in URGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $16.9M in Q1 2026. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • J. Goldman & Co held 212,775 shares of UroGen Pharma worth $7.83M as of Q2 2026.
  • J. Goldman & Co sold 726,095 UroGen Pharma shares in Q2 2026, an estimated $19.7M.
  • UroGen Pharma made up 0.2% of J. Goldman & Co's portfolio in Q2 2026, its #135 holding.
  • J. Goldman & Co first reported a position in UroGen Pharma in Q4 2025 and has held it in 3 quarters since.
  • J. Goldman & Co's UroGen Pharma position peaked at $16.9M in Q1 2026.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.